急性骨髄性白血病: 総合的な最新情報

Maria Jose Garcia-Rodriguez¹, Yorman Flores¹, Jose Salinas²

¹Hematopoietic Stem Cell Transplantation Program. Hematology Department Pontificia Universidad Católica de Chile Red de Salud Christus UC.

Current opinion in hematology

|September 5, 2025

まとめ

急性骨髄性白血病 (AML) の最近の進歩は,正確な診断と標的治療のための遺伝的変化に焦点を当てています. 測定可能な残留疾患 (MRD) のモニタリングは,AML患者の治療結果を改善します.

科学分野:

血液学
腫瘍学
分子遺伝学

背景:

急性骨髄性白血病 (AML) は,多様な遺伝的基盤を持つ複雑な血液学的悪性腫瘍です.
近年,AMLの分子環境を理解し,新しい治療戦略を開発する上で急速な進歩が見られました.

研究の目的:

2025年までにAMLの診断,分類,治療における最近の進歩をまとめること.
臨床医や研究者にAMLの管理に関する最新情報を提供すること.

主な方法:

最近の文献と臨床的発見のレビュー
更新されたWHOとICCの分類の分析
分子プロファイリングと標的治療に関するデータの合成

主要な成果:

新しい分類は,正確なAMLサブタイプ化のための遺伝的変化を強調しています.
分子プロファイリングはリスクの階層化を促進し,測定可能な残留疾患 (MRD) の役割を強調します.
標的薬 (FLT3,IDH1/2,メニン阻害剤) は,集中化学療法に不適した患者,または再発した患者を含む特定の患者グループに新しい選択肢を提供します.

結論:

ゲノムに関する洞察と新しい治療法によって AMLの管理はパーソナライズされた医療へと移行しています
MRDによる決定と維持療法を含む,発症後の戦略の進化は,長期的な疾患制御の改善を目的としています.
CAR-T細胞療法のような新興治療法は将来のAML治療に有望です

キーワード:

急性骨髄性白血病アロゲン性幹細胞移植標的型療法

さらに関連する動画

09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.6K

09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.1K

関連する概念動画

01:22

Bone Marrow Sampling and Transplants

491

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

491

01:27

Disorders of Leukocytes

1.1K

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...

1.1K

01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

3.3K

02:56

Treatment Resistant Cancers

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.4K

01:20

Overview of Hematopoiesis

4.7K

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...